Literature DB >> 1721092

SELEXION. Systematic evolution of ligands by exponential enrichment with integrated optimization by non-linear analysis.

D Irvine1, C Tuerk, L Gold.   

Abstract

Recently, novel technologies for isolation of nucleic acid molecules with specific biological activities have been reported. In each case, the enrichment process involves repeated rounds of selection from complex mixtures of nucleic acid sequences, followed by polymerase chain reaction (PCR) amplification of ligand sequences that function in the desired manner. Particular variations in experimental conditions can dramatically alter the outcome of these processes. In this study, we use mathematical analysis and computer simulation to predict which variations have the greatest impact and to develop strategies and guidelines for enhanced effectiveness. First, we perform reconstruction tests to demonstrate that a mathematical description based on equilibrium binding is sufficient to explain the high levels of enrichment attained in the laboratory after just a few rounds. Then, we show the expected enrichment for an extensive range of conditions; and, finally, we determine the optimum protein and nucleic acid concentrations to use for maximum enrichment, while also ensuring a high likelihood of recovering even the rare molecule that binds well. The strategies and guidelines for enhanced effectiveness are generally applicable to processes for systematic enrichment of DNA, RNA or peptide ligands and have been implemented in an interactive simulation program for integrated non-linear optimization of enrichment using any target of interest.

Mesh:

Substances:

Year:  1991        PMID: 1721092     DOI: 10.1016/0022-2836(91)90509-5

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  68 in total

1.  In vitro selection of RNA aptamers that bind special elongation factor SelB, a protein with multiple RNA-binding sites, reveals one major interaction domain at the carboxyl terminus.

Authors:  S J Klug; A Hüttenhofer; M Famulok
Journal:  RNA       Date:  1999-09       Impact factor: 4.942

2.  Estimation of SELEX pool size by measurement of DNA renaturation rates.

Authors:  J Charlton; D Smith
Journal:  RNA       Date:  1999-10       Impact factor: 4.942

3.  Splicing enhancement in the yeast rp51b intron.

Authors:  D Libri; A Lescure; M Rosbash
Journal:  RNA       Date:  2000-03       Impact factor: 4.942

4.  The tetranucleotide UCAY directs the specific recognition of RNA by the Nova K-homology 3 domain.

Authors:  K B Jensen; K Musunuru; H A Lewis; S K Burley; R B Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

5.  Selecting rRNA binding sites for the ribosomal proteins L4 and L6 from randomly fragmented rRNA: application of a method called SERF.

Authors:  U Stelzl; C M Spahn; K H Nierhaus
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

6.  Non-independence of Mnt repressor-operator interaction determined by a new quantitative multiple fluorescence relative affinity (QuMFRA) assay.

Authors:  T K Man; G D Stormo
Journal:  Nucleic Acids Res       Date:  2001-06-15       Impact factor: 16.971

7.  In vitro selection of integration host factor binding sites.

Authors:  S D Goodman; N J Velten; Q Gao; S Robinson; A M Segall
Journal:  J Bacteriol       Date:  1999-05       Impact factor: 3.490

8.  Determination and augmentation of RNA sequence specificity of the Nova K-homology domains.

Authors:  Kiran Musunuru; Robert B Darnell
Journal:  Nucleic Acids Res       Date:  2004-09-14       Impact factor: 16.971

Review 9.  Cytoplasmic RNA-binding proteins and the control of complex brain function.

Authors:  Jennifer C Darnell; Joel D Richter
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-08-01       Impact factor: 10.005

10.  RNA ligands to human nerve growth factor.

Authors:  J Binkley; P Allen; D M Brown; L Green; C Tuerk; L Gold
Journal:  Nucleic Acids Res       Date:  1995-08-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.